Seminars in Nuclear Medicine
Volume 31, Issue 3 , Pages 191-205 , July 2001

The fusion of anatomic and physiologic imaging in the management of patients with cancer

  • Ora Israel

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center, Technion, Haifa, Israel
    • Faculty of Medicine, Israel Institute of Technology, Technion, Haifa, Israel
    • Corresponding Author InformationAddress reprint requests to Ora Israel, MD, Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel 35254.
    • ,
  • Zohar Keidar

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center, Technion, Haifa, Israel
    • Faculty of Medicine, Israel Institute of Technology, Technion, Haifa, Israel
    • ,
  • Galina Iosilevsky

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center, Technion, Haifa, Israel
    • Faculty of Medicine, Israel Institute of Technology, Technion, Haifa, Israel
    • ,
  • Lise Bettman

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center, Technion, Haifa, Israel
    • Faculty of Medicine, Israel Institute of Technology, Technion, Haifa, Israel
    • ,
  • Jonathan Sachs

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center, Technion, Haifa, Israel
    • Faculty of Medicine, Israel Institute of Technology, Technion, Haifa, Israel
    • ,
  • Alex Frenkel

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center, Technion, Haifa, Israel
    • Faculty of Medicine, Israel Institute of Technology, Technion, Haifa, Israel

References 

  1. (abstr) Wahl RL. Imaging cancer in the new millennium: Form follows function. Radiology. 1999;213:25
  2. Weber DA, Ivanovic M. Correlative image registration. In: Semin Nucl Med. 24:1994;p. 311–323
  3. Maisey MN, Hawkes DJ, Lukawiecki-Vydelingum AM. Synergistic imaging. Eur J Nucl Med. 1992;19:1002–1005
  4. Treves ST, Mitchell KD, Habboush IH. Three-dimensional image alignment, registration and fusion. Q J Nucl Med. 1998;42:83–92
  5. (editorial) Coreia JA. Registration of nuclear medicine images. J Nucl Med. 1990;31:1227–1229
  6. (editorial) Shreve PD. Adding structure to function. J Nucl Med. 2000;41:1380–1382
  7. Kaplan IL, Swayne LC. Composite SPECT-CT images: Technique and potential applications in chest and abdominal imaging. AJR Am J Roentgenol. 1989;102:865–866
  8. Turkington TG, Jaszezak RJ, Pelizzari CA, et al. Accuracy of PET, SPECT and MR images of a brain phantom. J Nucl Med. 1993;34:1587–1594
  9. Pietrzyk U, Herholz K, Fink G, et al. An interactive technique for three-dimensional image registration: Validation for PET, SPECT, MRI and CT brain studies. J Nucl Med. 1994;35:2011–2018
  10. Chisin R, Pietrzyk U, Sichel JY, et al. Registration and display of multimodal images: Applications in the extracranial head and neck region. Otolaryngol. 1993;22:214–219
  11. Maintz JB, Viergever MA. A survey of medical image registration. Med Image Anal. 1998;2:1–36
  12. Wahl R, Quint LER, Cieslak RD, et al. “Anatometabolic” tumor imaging: Fusion of FDG-PET with CT or MRI to localize foci of increased activity. J Nucl Med. 1993;34:1190–1197
  13. Anderson JLR. A rapid and accurate method to realign PET scans utilizing image edge information. J Nucl Med. 1995;36:657–669
  14. Anderson JLR, Sundin A, Valind S. A method for coregistration of PET and MR images. J Nucl Med. 1995;36:1307–1315
  15. Davatzikos C. Spatial normalization of 3-D brain images using deformable models. J Comp Assist Tomogr. 1996;20:656–665
  16. Slomka PJ, Hurwitz GA, Stephenson J, et al. Automated alignment and sizing of myocardial stress and rest scans to three-dimensional normal templates using an image registration algorithm. J Nucl Med. 1995;36:1115–1122
  17. Lang TF, Hasegawa BH, Liew SC, et al. Description of a prototype emission-transmission computed tomography imaging system. J Nucl Med. 1992;33:1881–1887
  18. Beyer T, Townsend DW, Brun T, et al:A combined PET/CT scanner for clinical oncology J Nucl Med 41: 1369–1379
  19. Bocher M, Balan A, Krausz Y, et al. Gamma cameramounted anatomical x-ray tomography: Technology, system characteristics and first images. Eur J Nucl Med. 2000;27:619–627
  20. Patton JA, Delbeke D, Sandler MP, Image fusion using an integrated, dual-head coincidence camera with x-ray tubebased attenuation maps J Nucl Med 41: 1364–1368
  21. Loats H. CT and SPECT image registration and fusion for spatial localization of metastatic processes using radiolabeled monoclonals. J Nucl Med. 1993;34:562–566
  22. Kramer EL, Noz ME. CT-SPECT fusion for analysis of radiolabeled antibodies: Applications in gastrointestinal and lung carcinoma. Int J Rad Appl Instrum [B]. 1991;18:27–42
  23. Perault C, Schvartz C, Wampach H, et al. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. J Nucl Med. 1997;38:1234–1242
  24. Uematsu H, Sadato N, Yoshiharu Y, et al. Coregistration of FDG PET and MRI of the head and neck using normal distribution of FDG. J Nucl Med. 1998;39:2121–2127
  25. Hopper KD, Singapuri K, Finkel A. Body CT and oncologic imaging. Radiology. 2000;215:27–40
  26. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: Preliminary prospective evaluation. Radiology. 1994;191:371–377
  27. Phelps ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661–681
  28. Eubank WB, Mankoff DA, Schmiedl UP, et al. Imaging of oncologic patients: Benefit of combined CT and FDG PET in the diagnosis of malignancy. AJR Am J Roentgenol. 1998;171:1103–1110
  29. Freeny PC, Mark WM, Ryan JA, et al. Colorectal carcinoma evaluation with CT: Preoperative staging and detection of postoperative recurrence. Radiology. 1986;158:347–353
  30. McCloud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992;182:319–323
  31. Quint LE, Francis IR, Wahl RL, et al. Preoperative staging of non-small cell carcinoma of the lung: Imaging methods. AJR Am J Roentgenol. 1995;164:1349–1359
  32. Ito K, Kato T, Tadokoro M, et al. Recurrent rectal cancer and scar: Differentiation with PET and MR imaging. Radiology. 1992;182:549–552
  33. Studer UE, Schertz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol. 1990;144:243–245
  34. Medina Gallardo JF, Borderas Naranjo F, Torres Cansino M, et al. Validity of enlarged mediastinal nodes as markers of involvement by non-small cell lung cancer. Am Rev Respir Dis. 1992;146:1210–1212
  35. Goldstraw P, Mannan GM, Kaplan D, et al. Surgical management of non-small cell lung cancer with mediastinal node metastases (N2 disease). J Thor Cardiovasc Surg. 1994;107:19–28
  36. Arita T, Mastumoto T, Kuramitsu T, et al. Is it possible to differentiate malignant mediastinal nodes from benign nodes by size?. Chest. 1996;110:1004–1008
  37. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases. Eur J Nucl Med. 1998;25:1495–1501
  38. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology. 1999;213:530–536
  39. (editorial) Berlangieri SU, Scott AM. Metabolic staging of lung cancer. N Engl J Med. 2000;343:290–292
  40. Berlangieri SU, Scott AM, Knight SR, et al. F-18 fluorodeoxyglucose positron emission tomography in the noninvasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg. 1999;16(suppl 1):S25–S30
  41. Charron M, Beyer T, Bohnen NN, et al. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med. 2000;25:905–910
  42. Cook GI, Maisey MN, Fogelman I. Normal variants, artifacts and interpretive pitfalls in PET imaging with 18-fluorodeoxyglucose and carbon-11 methionine. Eur J Nucl Med. 1999;26:1363–1378
  43. Quiox E, Wolkove N, Hanley J, et al. Problems in radiographic estimation of response to chemotherapy and radiotherapy in small cell lung cancer. Cancer. 1988;62:489–493
  44. Iosilevsky G, Front D, Bettman L, et al. Uptake of gallium-67 citrate and [2-H3] deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med. 1985;26:278–282
  45. Israel O, Front D, Lam M, et al. Gallium-67 imaging in monitoring lymphoma response to treatment. Cancer. 1988;61:2439–2443
  46. (editorial) Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6:931–933
  47. Front D, Ben-Haim S, Israel O, et al. Lymphoma: Predictive value of Ga-67 scintigraphy after treatment. Radiology. 1992;182:359–363
  48. Radford JA, Cowan RA, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol. 1988;6:940–946
  49. Surbone A, Longo DL, DeVita VT, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management. J Clin Oncol. 1988;6:1832–1837
  50. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244–1253
  51. Dewan NA, Gupta NC, Redepenning LS, et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules: Potential role in evaluation and management. Chest. 1993;104:997–1002
  52. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188:487–490
  53. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumor receiving radiotherapy. J Nucl Med. 1991;32:1485–1490
  54. Krestin G, Steinbrich W, Friedman G. Recurrent rectal cancer: Diagnosis with MRI vs. CT. Radiology. 1988;168:307–311
  55. Cai J, Chu JCH, Recine D, et al. CT and PET lung image registration and fusion in radiotherapy treatment planning using the chamfer-matching method. Int J Radiat Oncol Biol Phys. 1999;43:883–891
  56. Bohm B, Schwenk W, Huche H, et al. Does methodic long-term follow up affect survival after curative resection of colorectal carcinoma?. Dis Colon Rectum. 1993;36:280–286
  57. Patt YZ, Lamki LM, Shanken J, et al. Imaging with Indium-111 labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J Clin Oncol. 1990;8:1246–1254
  58. Front D, Bar-Shalom R, Epelbaum R, et al. Early detection of lymphoma recurrence with gallium-67 scintigraphy. J Nucl Med. 1993;34:2101–2104
  59. Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med. 1991;32:623–648
  60. Weeks JC, Yeap BY, Canellos GP, et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991;9:1196–1203
  61. Cooper DL, Neumann RD, Caride VJ. A critical assessment of the prognostic value of gallium-67 scintigraphy in lymphoma. In: Freeman L editors. Nuclear Medicine Annual 2000. Philadelphia, PA: Lippincott Williams & Wilkins; 2000;p. 211–232
  62. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1991;23:1641–1674
  63. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. In: Semin Nucl Med. 30:2000;p. 150–185
  64. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG-PET imaging: Physiologic and benign variants. Radiographics. 1999;19:61–69
  65. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med. 2000;343:254–261
  66. Schaffler GJ, Groell R, Schoellnast H, et al. Digital image fusion of CT and PET data sets—Clinical value in abdominal/pelvic malignancies. J Comp Assist Tomogr. 2000;24:644–647
  67. (abstr) Front D, Israel O, Mor M, et al. A new technology of combined transmission (CT) and F-18 fluorodeoxyglucose (FDG) emission tomography (TET) in the evaluation of cancer patients. J Nucl Med. 2000;41:284
  68. Israel O, Mor M, Guralnik L, et al. The new technology of transmission and emission F-18 FDG tomography (FDG-TET) in the diagnosis and management of cancer patients. In: Presented at the 2000 ICP Meeting. Washington, DC. October 16–19, 2000;
  69. (abstr) Israel O, Mor M, Gaitini D, et al. A new technology for combined transmission and emission tomography (TET) in the diagnosis of tumor mass and tumor cancer. Radiology. 2000;217:222
  70. (suppl) Larson SM. Clinical radioimmunodetection 1978–1988: Overview and suggestions for standardization of clinical trials. Cancer Res. 1990;50:892–898
  71. Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med. 1992;33:803–814
  72. Press O, Early J, Appelbaum F, et al. Phase II trial of I-131 B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet. 1995;346:336–340
  73. De Nardo GL, O'Donnell RT, Oldham RK, et al. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 1998;13:213–223
  74. (suppl) Wahl RL, Zasadny KR, Mc Farlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: An update on the Michigan phase I experience. J Nucl Med. 1998;39:21S–27S
  75. Koral KF, Dewaraja Y, Li J, et al. Initial results for hybrid SPECT-conjugate-view tumor dosimetry in I-131 anti-B1 antibody therapy of previously untreated patients with lymphoma. J Nucl Med. 2000;41:1579–1586
  76. (suppl) Kramer E, Noz M, Liebes L, et al. Radioimmunodetection of non-small cell lung cancer using Tc-99m-anti-CEA IMMU-4 Fab' fragment: Preliminary results. Cancer. 1994;73:890–895
  77. Edri YE, Weasels BW, DeJaer R, et al. A new fiducial alignment system to overlay abdominal computed tomography or magnetic resonance anatomical images with radiolabeled antibody single-photon emission computed tomographic scans. Cancer. 1994;73:923–931
  78. Kramer E, Sanger J, Walsh C, et al. Contribution of SPECT to imaging of gastrointestinal adenocarcinoma with In-111 labeled anti-CEA monoclonal antibody. AJR Am J Roentgenol. 1988;151:697–703
  79. Kramer EL, Noz ME, Sanger JJ, et al. CT-SPECT fusion to correlate radiolabeled monoclonal antibody uptake with abdominal CT findings. Radiology. 1989;172:861–865
  80. Liehn JC, Loboguerrero A, Perault C, et al. Superimposition of computed tomography and single photon emission tomographic images in the pelvis: Validation in patients with colorectal or ovarian carcinoma recurrence. Eur J Nucl Med. 1992;19:186–194
  81. Scott AM, Macapinlac HA, Divgi CR, et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med. 1994;35:1976–1984
  82. (suppl) Katyal S, Kramer EL, Noz ME, et al. Fusion of immunoscintigraphy single photon emission tomography (SPECT) with CT of the chest in patients with non-small cell lung cancer. Cancer Res. 1995;55:5759S–5763S
  83. Scott AM, Macapinlac H, Zhang JJ, et al. Clinical applications of fusion imaging in oncology. Nucl Med Biol. 1994;21:775–784
  84. Scott MA, Macapinlac HA, Zhang JJ, et al. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med. 1995;36:100–103
  85. Fujita A, Hyodog H, Kawamura Y, et al. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med. 2000;25:440–442
  86. Even-Sapir E, Keidar Z, Sachs J, et al: The new technology of combined transmission and emission tomography (TET) in the evaluation of endocrine neoplasms. J Nucl Med (in press)
  87. Kaplan WD, Jochelson MS, Herman TS, et al. Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphomas. J Clin Oncol. 1990;8:1966–1970
  88. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. In: Semin Nucl Med. 25:1995;p. 60–71
  89. Front D, Bar-Shalom R, Israel O. The continuing role of Gallium-67 scintigraphy in the age of receptor imaging. In: Semin Nucl Med. 25:1997;p. 68–84
  90. Israel O, Jerushalmi J, Ben-Haim S, et al. Normal and abnormal Ga-67 SPECT anatomy in patients with lymphoma. Clin Nucl Med. 1990;15:334–345
  91. Even-Sapir E, Bar-Shalom R, Israel O, et al. Singlephoton emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake. J Clin Oncol. 1995;13:942–946
  92. (abstr) Kaplan IL, Swayne LC. Composite gallium SPECT-CT images in the evaluation of recurrent lymphoma. J Nucl Med. 1989;30:874–875
  93. (abstr) Israel O, Yefremov N, Mor M, et al. A new technology of combined transmission (CT) and emission (Ga-67) tomography (TET) in the evaluation of patients with lymphoma. J Nucl Med. 2000;41:70
  94. (abstr) Israel O, Yefremov N, Mor M, et al. Combined transmission and Ga-67 emission tomography (TET) in the evaluation of response to treatment and diagnosis of recurrence in patients with lymphoma. Eur J Nucl Med. 2000;27:1160
  95. (commentary) Wagner HN. Fused image tomography: An integrating force. J Nucl Med (newsline). 1999;39:13N–32N
  96. (commentary) Wagner HN. The Internet: The road to smart nuclear medicine. J Nucl Med (newsline). 2000;40:9N–34N
  97. Coleman RE. Predictions for nuclear medicine in the next decade: Commentary. Radiology. 1998;208:6–7

PII: S0001-2998(01)80019-2

doi: 10.1053/snuc.2001.23525

Seminars in Nuclear Medicine
Volume 31, Issue 3 , Pages 191-205 , July 2001

Article Tools